Hwanin Pharmaceutical announced on the 29th that its preliminary consolidated operating profit for the second quarter of 2026 surged 192.3% year-on-year to KRW 7.894 billion.

■ Q2 2026 Performance Summary (Consolidated Basis) Revenue reached KRW 71.419 billion, up 11.4% from KRW 64.135 billion in the same period last year. Compared to the previous quarter (KRW 71.176 billion), it grew by 0.3%. Operating profit stood at KRW 7.894 billion, a significant increase of 192.3% from KRW 2.701 billion in the same period last year. However, it decreased by 15.8% compared to the previous quarter (KRW 9.381 billion). Profit before income tax from continuing operations was KRW 9.736 billion, up 183.3% year-on-year, but down 2.5% compared to the previous quarter. Net income was KRW 7.651 billion, up 140.0% year-on-year and up 2.5% from the previous quarter. Net income attributable to owners of the parent company was also KRW 7.651 billion.

■ H1 2026 Cumulative Performance (Consolidated Basis) Cumulative revenue for the first half (January–June) was KRW 142.595 billion, up 14.7% from the same period last year. Cumulative operating profit surged 116.5% to KRW 17.275 billion, while cumulative profit before income tax from continuing operations increased 115.8% to KRW 19.717 billion. Additionally, cumulative net income rose 82.0% to KRW 15.117 billion.

Meanwhile, on a non-consolidated (separate) financial statement basis, first-half performance showed revenue of KRW 142.074 billion, operating profit of KRW 19.616 billion, profit before income tax from continuing operations of KRW 18.845 billion, and net income of KRW 14.246 billion.

The company stated, "This performance is a preliminary figure based on Korean International Financial Reporting Standards (K-IFRS) consolidated financial statements, and is an internal settlement result that has not been reviewed by an external auditor," adding, "It may be subject to change during future review processes."